Stay updated on Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi
Sign up to get notified when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.

Latest updates to the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page
- Check5 days agoChange DetectedPublications section added: Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial. This update does not alter the study design, eligibility criteria, endpoints, or enrollment.SummaryDifference0.0%

- Check12 days agoChange DetectedThe Publications section now states entries are automatically filled from PubMed and may not all pertain to the study, and the revision tag changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRemoved the government funding/status notice that warned about potential delays and operating status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check27 days agoChange DetectedReplaced the Taiwan site entry 'Tainan City, Taiwan, 70403' with 'Tainan, Taiwan, 70403'.SummaryDifference0.0%

- Check41 days agoChange DetectedThe new screenshot shows only minor cosmetic/UI adjustments to the Study Details page, with no changes to core data such as eligibility criteria, primary/secondary outcomes, enrollment, or location. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check63 days agoChange DetectedAdded an operational status notice and updated version to v3.2.0; removed the old version v3.1.0.SummaryDifference1%

Stay in the know with updates to Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.